Wire · opportunities
Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 September 2026 · Fusion42 review
Nanexa and Novo Nordisk have entered a global exclusive license and collaboration agreement worth up to EUR 1.165 billion for Nanexa's PharmaShell® drug delivery platform targeting peptide drugs in obesity, type 2 diabetes, and cardiometabolic diseases. Novo will lead development and commercialization of up to five development programs with different dosing frequencies, while Nanexa will receive upfront, milestone payments, and royalties.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Nanexa's PharmaShell® platform just became a proven path to big pharma partnerships with huge upfront and milestone payments. If you build drug delivery tech, you now need to map how to make your platform relevant to obesity and diabetes treatments.
◆ Coverage
1 source · 26 Sep 2026
◆ Related on Wire
◆ Topics